Skip to main content

RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. A

Social Author Name
Dr. John Cush
Tweet Content
RheumNow’s expanded coverage of the #EULAR2025 Annual meeting is sponsored in part by Johnson & Johnson and UCB. All content chosen by RheumNow & its Faculty.

Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out.

Social Author Name
Dr. John Cush
Tweet Content
Secukinumab promise in PMR is real GCA is getting steroid-sparing therapy choices, and PMR doesn’t want to miss out. Most PMR patients with current therapy approaches incur multiple grams of cumulative prednisolone exposure, even though they’re often exactly the kind of https://t.co/GuD0l7zSfj

Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet 🔴Performance tests (SPPB) were associated with 🔴Global fun

Social Author Name
Nelly ZIADE 🍀
Tweet Content
Among 200 #axSpA pts from Rheumazentrum Ruhrgebiet 🔴Performance tests (SPPB) were associated with 🔴Global functioning and health (ASAS-HI and other PROs) What does this mean? Improving physical performance could enhance PROs & QOL #EULAR2025 POS# @RheumNow @XBaraliakos https://t.co/P3Q5NDvtoj

#D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activ

Social Author Name
Nelly ZIADE 🍀
Tweet Content
#D2M_axSpA_saga 🇬🇷 Prevalence of D2M axSpA in 395 patients: 10.1% Associated factors: 🔹️High disease activity at diagnosis 🔹️Comorbidities (high BMI, smoking, depression) 🔹️Unemployment Kougkas et al. POS#0121 #EULAR2025 @rheumnow https://t.co/vcPcTATTx5

What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory Ps

Social Author Name
Nelly ZIADE 🍀
Tweet Content
What's the difference between PIPsA & NIPsA? (Persistent Inflammatory confirmed by IMAGING vs. Non inflammatory PsA) 🔹️Cross-sectional study 🔹️517 pts under b/tsDMARDs 🔹️10.3% D2T 🔹️57% PIPsA / 43% NIPsA 👇 Distinct phenotypes 👇 OP0176 #EULAR2025 @rheumnow https://t.co/YGHpbeE6ws

What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registri

Social Author Name
Nelly ZIADE 🍀
Tweet Content
What happens to the prevalence of D2T PsA if we use different parameters in its definition? Data from 5 Nordic registries including 13,872 patients showed a variation from 37% (less stringent) to 0.6% (more stringent)! OP0177 #EULAR2025 @rheumnow https://t.co/QbF15t3Zrz

#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-

Social Author Name
Md Yuzaiful Md Yusof
Tweet Content
#EULAR2025 Abstr#OP0319 Multicentre study in Canada showed no difference in longterm Lung Transplant outcomes among IIM-ILD, SSc-ILD & IPF. Some differences: IIM-ILD was progressive pre-transplant with prolonged hospitalisation post-surgery. For us to be aware @RheumNow https://t.co/eFdY4XGtlj

🚨Diagnostic delays are real in axSpA: -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA. -Increases

Social Author Name
Adela Castro
Tweet Content
🚨Diagnostic delays are real in axSpA: -Can lead to more extra-msk manfieststions (EMMs) in PsA and axSpA. -Increases disease burden and productivity losses. -EMMs can present before articular sx -Uveitis and IBD associated with longer dx delays. -Diagnosis has improved since https://t.co/rWMwG7Ewwe

#guidelines everywhere @jeffsparks presents points of interest from #ACR #ILD #recommendations - a joint venture with

Social Author Name
Janet Pope
Tweet Content
#guidelines everywhere @jeffsparks presents points of interest from #ACR #ILD #recommendations - a joint venture with American College of Chest Physicians While simultaneously the EULAR ILD recommendations are being unveiled! @RheumNow #EULAR2025 @eular_org @ACRheum https://t.co/cfHrqIAbx9
Subscribe to
×